Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for MET exon 14 and MET-amplified non-small-cell lung cancer, drawn from the whole corpus: 20 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
MET amplification has no agreed threshold and results differ between assays.
Peripheral oedema limits the dose of every MET inhibitor and has no good treatment.
Whether MET inhibitors should be combined with chemotherapy or immunotherapy first line in exon 14 disease is untested.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
ORR 28.
A milestone in how this cancer is treated.
Breakthrough Therapy designation, c-MET overexpressing NSCLC
A milestone in how this cancer is treated.